Clague Laura
Known title: Chief Financial OfficerCIK: 0001388773
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Genasys Secures $1.5M in New Orders and National Guard Contract. Genasys reported receiving $1.5 million in new orders for its voice broadcast and mass notification systems. Additionally, the company secured a follow-on order from the National Guard for LRAD devices, bringing total orders to $8.5 million. Butte County in California also selected Genasys Protect to improve its wildfire preparedness and emergency management capabilities.
Transaction History
| LAB | ▲ Buy | Grant | 26,376 | $0 | 6/14/2023 | View on chart |
| LAB | ▲ Buy | Grant | 30,914 | $0 | 6/15/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,375 | $30K | 5/11/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 825 | $18K | 5/10/2022 | View on chart |
| GNSS | ▲ Buy | Option Exercise | 50,000 | $67K | 4/27/2022 | View on chart |
| GNSS | ▲ Buy | Grant | 30,000 | — | 3/15/2022 | View on chart |
| GNSS | ▼ Sell | Open Market | 13,716 | $43K | 2/23/2022 | View on chart |
| GNSS | ▲ Buy | Option Exercise | 20,000 | $43K | 2/23/2022 | View on chart |
| TVTX | ▲ Buy | Grant | 9,840 | $0 | 1/31/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,238 | $34K | 1/31/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,063 | $52K | 1/24/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 7,500 | $206K | 1/11/2022 | View on chart |
| TVTX | ▲ Buy | Grant | 7,500 | $0 | 1/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Travere Shares Drop 6.7% Ahead of New FILSPARI Data
Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.
Travere Shares Drop 6.7% Ahead of New FILSPARI Data. Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.